MANAGEMENT

MANAGEMENT

Kazuma Kishida
Representative Director ,CEO&Co-founder

Kazuma Kishida

Graduated from Waseda University, and began a career in M&A advisory at the U.S.-based investment bank Houlihan Lokey. Co-founded Dioseve, Inc. in 2021 and currently serves as the company’s Representative Director.

Kazuma Kishida
Nobuhiko Hamazaki  Ph.D.
Scientific Advisor & Co-founder

Nobuhiko Hamazaki Ph.D.

Dr. Hamazaki is an assistant professor specializing in stem cell and genomics technologies. He researches the mechanism of infertility and developmental diseases using stem cells and genomics. He was trained at Kyushu University, a top school globally for fertility studies.

Nobuhiko Hamazaki  Ph.D.
Yasunari Seita Ph.D.
Principal Scientist

Yasunari Seita Ph.D.

Obtained a Doctorate degree from Azabu University, and worked as a researcher at the Child Health Institute of New Jersey, Shiga University of Medical Science, and University of Pennsylvania.
Joined Dioseve in 2023

Yasunari Seita Ph.D.
Shinji Takahashi Ph.D.
Head of Research & Clinical Development

Shinji Takahashi Ph.D.

After joining Mitsui Pharmaceutical Industries in 1994, engaged in research and development in the pharmaceutical industry for over 30 years, serving as a Research Scientist in Drug Discovery and Applied Pharmacology and a Project Manager in Clinical Development at Astellas Pharma Inc., a Senior Researcher at the Drug Discovery Research Institute of Taisho Pharmaceutical Co., Ltd., and a Director of Research and Development at Surv BioPharma Inc.Obtained a Doctorate degree from Yokohama City University in 2002.
Joined Dioseve in 2026

Shinji Takahashi Ph.D.
Kasane Kishi DVM, Ph.D.
Technical Manager/Senior Scientist

Kasane Kishi DVM, Ph.D.

Obtained a Doctorate degree from the Graduate School of Agricultural and Life Sciences, The University of Tokyo in 2018 and worked as a pharmacologist in Astellas Pharma Inc.
Joined Dioseve as Senior Scientist in 2023

Kasane Kishi DVM, Ph.D.
Kosei Ishiguro Ph.D.
Senior Development Manager

Kosei Ishiguro Ph.D.

Obtained a doctorate from the University of Tsukuba, and worked as a senior researcher at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg and at the Institute of Agrobiological Sciences, NARO (NIAS) in Tsukuba.
Joined Dioseve in 2023.

Kosei Ishiguro Ph.D.
Katsuhiko Hayashi  Ph.D.
Scientific Advisor

Katsuhiko Hayashi Ph.D.

Professor, Graduate School of Medicine, Osaka University. Selected as one of Nature magazine’s “10 People of the Year” in 2023 and TIME magazine’s “Most Influential People” in 2024. World leader in germ cell research. World’s leading expert in germ cell research.

Katsuhiko Hayashi  Ph.D.
Yoshinori Shinoki
Clinical Development Advisor

Yoshinori Shinoki

Graduated from the Department of Biopharmaceuticals, Kyoto Pharmaceutical University.
Launched the Clinical Development Department at Eli Lilly Japan and Parexel International, and since 2015, General Manager of JConsulting Management Department.

Yoshinori Shinoki
Nobuhiko Suganuma M.D., Ph.D.
Medical Advisor

Nobuhiko Suganuma M.D., Ph.D.

Professor Emeritus at Kyoto University, Visiting Professor at Fujita Health University. Distinguished member and specialist in obstetrics and gynecology of the Japan Society of Obstetrics and Gynecology, distinguished member and specialist in reproductive medicine of the Japan Society for Reproductive Medicine, board member of the Japan Society of Fertilization and Implantation, honorary member of the Japan Society of Maternal Health, honorary member of the Japan Society for Sexual Science, president of the Japan Uterus Transplantation Research Society. Graduated from the School of Medicine, Nagoya University.

Nobuhiko Suganuma M.D., Ph.D.
Nobuhiro Noro Ph.D.
Research and Development Advisor

Nobuhiro Noro Ph.D.

Obtained the degree of Ph.D. at the Faculty of Science, Kyoto University, engaged in several research areas such as neurobiology and celular biology. Joined GlaxoSmithKline Co., Ltd. in 1997 and worked in drug discovery and late phase clinical development. Appointed as an corporate officer of the company in 2011. Appointed as the Chief Scientific Officer of Bonac Corporation in 2021, engaged in the research & development in nucleic acid medicine and corporate management.

Nobuhiro Noro Ph.D.
ページトップへ